Obesity is a problem in many parts of the world, and its prevalence is increasing rapidly. Inhibition of pancreatic lipase to inhibit triglyceride hydrolysis can prevent obesity and reduce its prevalence, so drugs that can inhibit pancreatic lipase are very useful as anti-obesity. Orlistat is the single most successful approved pancreatic lipase inhibitor compound, but its use is still limited due to its relatively high price and several side effects. A safe and effective alternative to pancreatic lipase inhibitors is urgently needed. Metabolites in wungu leaves (Graptophyllum pictum (L.) Griff.), which is a traditional Indonesian plant, have potential as an anti-obesity. This study aims to determine the effect of wungu leaf metabolites on lipase as an anti-obesity. This study began with an in vitro test, which tested lipase activity with the addition of wungu leaf extract. The best extract samples were then tested with LC-MS to determine the profile of secondary metabolites. Furthermore, an in silico approach was carried out by paying attention to the LIPINSKI and ADMET rules, so as to obtain potential medicinal compounds. It can be concluded that wungu leaf extract has the potential to be developed as an alternative anti-obesity active ingredient derived from archipelago herbs.
Khairani et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: